Reason for request

Inclusion on the list of medicines refundable by National Health Insurance (B/2 and B/7) and approved for hospital use (B/10) in the extension of indication: "Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis".


Clinical Benefit


The actual benefit of ARIXTRA 2.5 mg is moderate.

Clinical Added Value

no clinical added value

The Committee considers that ARIXTRA 2.5 mg does not contribute any improvement in actual benefit (level V) in the treatment strategy in view of the uncertainty regarding the clinical benefit of a 45-day treatment period in the very varied population of patients with isolated SVT.

Contact Us

Évaluation des médicaments

See also